Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment

2024-9-14

JARID2 activation by NFYA promotes stemness of triple-negative breast cancer cells through the PI3K/AKT pathway

2024-9-10

Implementing Machine Learning to Predict Survival Outcomes in Patients with Resected Pulmonary Large Cell Neuroendocrine Carcinoma

2024-9-6

Current immunotherapy techniques in meningioma

2024-9-4

Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia

2024-9-2

Nature and nurture: addressable causes of disparities in prostate cancer care and survivorship in Black men

2024-8-30

Sacituzumab govitecan for hormone receptor–positive HER2-negative advanced breast cancer

2024-8-29

Intra-arterial administration of PSMA-targeted radiopharmaceuticals for brain tumors: is the era of interventional theranostics next?

2024-8-29

PARP inhibitor resistance mechanisms and PARP inhibitor derived imaging probes

2024-8-28

Tumor grade and progesterone receptor status in predicting benefit of chemotherapy in high genomic risk breast cancer

2024-8-17

Strategies for the prevention or reversal of PARP inhibitor resistance

2024-8-15

Efficacy of doxorubicin and lipiodol therapy by trans-arterial chemoembolization in Hepatocellular Carcinoma Egyptian patients and relation to genetic polymorphisms

2024-8-13

An evaluation of mitomycin-containing reverse thermal gel for the treatment of low-grade upper tract urothelial carcinoma

2024-8-12

Progress in histology specific treatments in soft tissue sarcoma

2024-8-5

Targeted therapies in advanced biliary malignancies: a clinical review

2024-8-4

UNDERSTANDING the LINK BETWEEN ASPARTAME and CANCER

2024-7-31

Immune-related adverse events associated with Mogamulizumab: a comprehensive review of the literature

2024-7-23

BEVACIZUMAB-CONTAINING TREATMENT for RELAPSED or REFRACTORY WILMS TUMOR

2024-7-23

PROTAC’ing the androgen receptor and other emerging therapeutics in prostate cancer

2024-7-22

Risks and benefits of sentinel lymph node evaluation in the management of endometrial intraepithelial neoplasia

2024-7-18

Elevated DKK1 expression: A promising prognostic biomarker and therapeutic target in head and neck squamous cell carcinoma

2024-7-15

The new life of ibrutinib therapy in CLL: enhancing personalized approaches

2024-7-15

Current practices in oncofertility counseling: updated evidence on fertility preservation and post-treatment pregnancies in young women affected by early breast cancer

2024-7-9

Screening of genes related to programmed cell death in esophageal squamous cell carcinoma and construction of prognostic model based on transcriptome analysis

2024-7-8

Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review

2024-7-8

First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC

2024-7-1

Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?

2024-7-1

Highlights from the 2024 ASCO Genitourinary Symposium: focus on urothelial and prostate cancer

2024-6-27

MULTITARGETED POLYPHARMACOTHERAPY for CANCER TREATMENT. THEORETICAL CONCEPTS and PROPOSALS.

2024-6-24

Augmenting the landscape of Chimeric Antigen Receptor T-cell therapy

2024-6-24

2024 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma

2024-6-24

Treatment options in the advanced and recurrent setting for endometrial cancer: an update

2024-6-19

Nomogram and calculator for predicting the prognosis of patients with giant hepatocellular carcinoma

2024-6-17

The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis

2024-6-16

Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer

2024-6-14

Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives

2024-6-11

Adenoid Cystic carcinoma of minor salivary glands (AdCCmSG): a multidisciplinary update

2024-6-4

Bispecific antibodies in the treatment of Relapsed/Refractory large B-cell lymphoma

2024-6-3

First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced <i>EGFR</i> -mutated NSCLC: a meta-analysis of randomized phase III trials

2024-5-30

Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review

2024-5-30

Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma

2024-5-26

Current management of familial adenomatous polyposis

2024-5-24

Risk-stratification for treatment de-intensification in WNT-pathway medulloblastoma: finding the optimal balance between survival and quality of survivorship

2024-5-24

The trend toward more target therapy in pancreatic ductal adenocarcinoma

2024-5-23

Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis

2024-5-23

Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?

2024-5-11

Is there a link between talcum powder, oxidative stress, and ovarian cancer risk?

2024-5-8

The role of planetary health in urologic oncology

2024-5-6

The PI3K signaling pathway; from normal lymphopoiesis to lymphoid malignancies

2024-5-1

Efficacy and safety of neoadjuvant therapy for HR-positive/HER2-negative early breast cancer: a Bayesian network meta-analysis

2024-5-1